The abstract is read at the publisher; the summary is JClub's.
In the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS), combining plasma pTau217 with modified cued recall performance identifies cognitively stable individuals with markedly elevated 7-year risk of clinical impairment.
- Why it matters: People with Down syndrome face high Alzheimer’s disease risk, but routine, accessible screening tools to refine prognosis are limited.
- What they did: Using ABC-DS data, the study built a low-burden multimodal framework that integrates plasma pTau217 with modified cued recall task performance to stratify future impairment risk.
- The result: The approach improves prognostic accuracy for clinical management and enables more efficient trial enrichment in Down syndrome over the next 7 years.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.